Compare ENS & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ENS | ABVX |
|---|---|---|
| Founded | 1991 | 2013 |
| Country | United States | France |
| Employees | 9200 | 67 |
| Industry | Industrial Machinery/Components | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 9.7B |
| IPO Year | 2004 | N/A |
| Metric | ENS | ABVX |
|---|---|---|
| Price | $222.03 | $119.44 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $193.00 | $131.31 |
| AVG Volume (30 Days) | 268.5K | ★ 768.7K |
| Earning Date | 05-20-2026 | 03-23-2026 |
| Dividend Yield | ★ 0.51% | N/A |
| EPS Growth | ★ 38.31 | N/A |
| EPS | ★ 5.65 | N/A |
| Revenue | ★ $216,125,000.00 | N/A |
| Revenue This Year | $4.49 | $52.14 |
| Revenue Next Year | $3.41 | $4,132.27 |
| P/E Ratio | $38.34 | ★ N/A |
| Revenue Growth | ★ 15.85 | N/A |
| 52 Week Low | $76.60 | $5.59 |
| 52 Week High | $239.69 | $148.83 |
| Indicator | ENS | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 56.21 | 52.33 |
| Support Level | $152.19 | $107.29 |
| Resistance Level | N/A | $129.73 |
| Average True Range (ATR) | 7.38 | 4.75 |
| MACD | -1.79 | -0.46 |
| Stochastic Oscillator | 44.39 | 51.69 |
EnerSys provides stored energy solutions for industrial applications. It also manufactures and distributes energy systems solutions and motive power batteries, specialty batteries, battery chargers, power equipment, battery accessories, and outdoor equipment enclosure solutions to customers. Energy Systems that combine enclosures, power conversion, power distribution, and energy storage are used in the telecommunication and broadband, utility industries, uninterruptible power supplies, and numerous applications requiring stored energy solutions. Its segments include Energy Systems, Motive Power, and Specialty.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.